GlassScriptPhysician profile
Lamson DO Nguyen
NPI 1255954988
$732.08
in general payments reported to CMS, 2019-2025
14 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $197 · 2024: $389 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $633 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $633.08 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $339.80 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Merck Sharp & Dohme LLC | $56.31 | 2023-2024 | Keytruda, Welireg, Lynparza |
| Celgene Corporation | $48.72 | 2023-2024 | Pomalyst |
| Janssen Biotech, INC. | $38.88 | 2024 | Erleada, Akeega |
| Rigel Pharmaceuticals, INC. | $29.49 | 2024 | Tavalisse, Rezlidhia |
| Amgen INC. | $28.75 | 2023 | Evenity, Prolia |
| Abbvie INC. | $27.82 | 2025 | |
| Seagen INC. | $27.67 | 2023 | Tukysa |
| E.R. Squibb & Sons, L.L.C. | $25.64 | 2024 | Opdivo |
| Eisai INC. | $25.46 | 2024 | |
| Pharmaessentia USA Corporation | $23.50 | 2023 | Besremi |
| Gilead Sciences, INC. | $21.04 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.47 | 2024 | Ninlaro |
| Pharmacyclics LLC, An Abbvie Company | $18.53 | 2023 | Epkinly, Imbruvica |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lamson Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.